Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Concomitant deletion of Shp-1 and Shp-2 in T cells fails to improve anticancer responses

ABSTRACT: Anticancer T cells acquire a dysfunctional state characterized by poor effector function and expression of inhibitory receptors, such as programmed cell death protein 1 (PD-1). Blockade of PD-1 signalling leads to T cell reinvigoration and is increasingly applied as an effective anticancer treatment. Recent work challenged the commonly held view that the phosphatase Src homology 2 (SH2) domain–containing phosphatase (SHP)-2 is essential for the molecular cascade downstream PD-1, suggesting functional redundancy with the homologous phosphatase SHP-1. Therefore, we investigated the effect of concomitant SHP-1 and 2 deletion in T cells by knocking out these phosphatases under the CD4cre promoter. In vivo results not only indicate that Shp-1/2 deletion is insufficient to ameliorate tumour control, but also that it impairs the therapeutic effects of anti-PD1 treatment, affecting tumour-infiltrating CD8+ T cells. Notably, acute deletion of Shp-1/2 in effector T cells also fails to improve tumour control. In vitro results show that Shp-1/2-deleted CD8+ T cells exhibit impaired expansion due to a survival defect and proteomics analysis reveals substantial alterations in their proteome, including in apoptosis-related pathways. This data indicates that concomitant ablation of SHP-1/2 in polyclonal T cells fails to improve their anticancer properties, implying that caution shall be taken when considering their inhibition for immunotherapeutic approaches.

INSTRUMENT(S): Q Exactive

ORGANISM(S): Mus Musculus (mouse)

TISSUE(S): Cell Suspension Culture, Leukocyte

DISEASE(S): Colon Cancer,Lymphoma

SUBMITTER: Laura Spinelli

LAB HEAD: Doreen Cantrell

PROVIDER: PXD034897 | Pride | 2022-09-29

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	LS-A1-1.raw	Raw
	LS-A1-2.raw	Raw
	LS-A1-3.raw	Raw
	LS-A1-4.raw	Raw
	LS-A1-5-rpt.raw	Raw

Items per page:

1 - 5 of 52

Similar Datasets

Myeloid-specific SHP-2 ablation alters the fate commitment of myeloid cells and induces anti-tumor immunity

Project description:We generated mice with conditional targeting of the Ptpn11 gene (encoding for Shp-2) in T cells (Shp-2fl/flLckCre) or myeloid cells (Shp-2fl/flLysMCre). Although no difference in tumor growth was observed between Shp-2fl/flLckCre and control mice and both groups were similarly benefitted by PD-1 blockade, Shp-2fl/flLysMCre mice had significantly diminished tumor growth that was not further decreased by anti-PD-1 treatment. As revealed by RNA-seq, myeloid-specific Shp-2 ablation was paralleled by expansion of activated myeloid cells and macrophages with molecular signatures of enhanced neutrophil and macrophage differentiation, phagocytosis, antigen-presenting function, TLR and type I IFN signaling, chemokine production, and expression of immunostimulatory molecules, which promoted T cell recruitment and activation.

2022-10-26 | GSE187394 | GEO

MicroRNA profiling of mouse wild type and SHP knock-out liver

Project description:The microRNA expression profiles between wild type 2-month old mouse liver and small heterodimer partner (SHP) knockout mouse liver was compared using microRNA array.

2008-09-13 | E-MEXP-1721 | biostudies-arrayexpress

CPDR tumor-benign 80 genechip dataset

Project description:From over 300 patients two groups were selected which had prostate tumors with either well differentiated (WD) or poorly differentiated (PD) after radical Prostatectomy. The PD group had Gleason score 8-9, seminal vesicle invasion, and poorly differentiated tumor cells; the WD group had Gleason score 6-7, no seminal vesicle invasion, and well to moderately differentiated tumor cells. LCM compatible specimens were selected from age and race (Caucasians) matched PD or WD patients with no family history of CaP. Matching normal epithelal cells were also selected for the analysis. From 40 patients specimens were obtained under an IRB-approved protocol from patients treated with radical prostatectomy (RP) at Walter Reed Army Medical Center (WRAMC).

2011-09-28 | E-GEOD-32448 | biostudies-arrayexpress

mRNA-Seq of head tissue from Drosophila pseudoobscura

Project description:We sequenced mRNA from head tissue of females and male of Drosophila pseudobscura to identify genes differentially expressed between the sexes and sex-specific alternative splicing events. For data usage terms and conditions, please refer to http://www.genome.gov/27528022 and http://www.genome.gov/Pages/Research/ENCODE/ENCODEDataReleasePolicyFinal2008.pdf Comparison of expression profiles in female and male head tissue from D. pseudobscura

2010-01-26 | E-GEOD-19989 | biostudies-arrayexpress

SHP-1 dependent dephosphorylation of Histone H2B acts as a molecular switch to facilitate transcription

Project description:1.Comparison of chromatin occupancy of H2BUb and RNA Polymerase II in SHP-1 WT and KO MCF7 cells. Paired end sequencing (2X100 bp) was performed on the Illumina HiSeq X ten. 2.Identification of the SHP-1 binding site in MCF7 cells using ChIP Seq. Paired end sequencing (2X100 bp) was performed on the Illumina Nextseq 2000 platform.

2022-06-01 | E-MTAB-10295 | biostudies-arrayexpress

mRNA-Seq of head tissue from Drosophila melanogaster

Project description:We sequenced mRNA from head tissue of females and male of Drosophila melanogaster to identify genes differentially expressed between the sexes and sex-specific alternative splicing events. For data usage terms and conditions, please refer to http://www.genome.gov/27528022 and http://www.genome.gov/Pages/Research/ENCODE/ENCODEDataReleasePolicyFinal2008.pdf Comparison of expression profiles in female and male head tissue from D. melanogaster

2010-04-08 | E-GEOD-20348 | biostudies-arrayexpress

mRNA-Seq of head tissue from Drosophila mojavensis

Project description:We sequenced mRNA from head tissue of females and male of Drosophila mojavensis to identify genes differentially expressed between the sexes and sex-specific alternative splicing events. For data usage terms and conditions, please refer to http://www.genome.gov/27528022 and http://www.genome.gov/Pages/Research/ENCODE/ENCODEDataReleasePolicyFinal2008.pdf Comparison of expression profiles in female and male head tissue from D. mojavensis

2010-04-11 | E-GEOD-20882 | biostudies-arrayexpress

Proteomics analysis of Polyphyllin D-treated triple-negative breast cancer cells reveal the anticancer mechanisms of Polyphyllin D

Project description:Polyphyllin D (PD) is the active component from an Asian traditional medicinal herb Paris polyphylla, and has been found to hold significant anticancer activity in vivo or in vitro. However, the mechanism through which PD exerts its anticancer effects in triple-negative breast cancer (TNBC) remains unclear. Our study was presented to evaluate the anticancer effect and the potential mechanisms of PD in two TNBC cell lines, namely BT-549 and MBA-MB-231. Through comprehensively comparing the liquid chromatography-tandem mass spectrometry (LC-MS/MS) data of PD-treated and -untreated BT-549 and MBA-MB-231 cells, we found PD could activate oxidative phosphorylation pathway in BT-549 cells and inhibit spliceosome function in MDA-MB-231 cells, suggesting that the anticancer effect of PD may be cell type-specificity dependent. Moreover, we found that nodal modulator 2/3 (NOMO2/3) were down-regulated both in PD-treated BT-549 and MBA-MB-231 cells, suggesting NOMO2/3 may be the potential target of PD. Whether NOMO2/3 are the upstream modulators of oxidative phosphorylation pathway and Spliceosome need further validation. In conclusion, a comprehensive proteomics study was performed on PD-treated or untreated TNBC cells, revealing the anticancer mechanisms of PD.

2023-03-20 | PXD040990 |

Gene expression profile of mouse breast cancer V720 cells treated with vehicle or PD 0332991

Project description:D-cyclins represent components of cell cycle machinery. To test the efficacy of targeting D-cyclins in cancer treatment, we engineered mouse strains which allow acute and global ablation of individual D-cyclins in a living animal. Ubiquitous shutdown of cyclin D1 or inhibition of cyclin D associated kinase activity in mice bearing ErbB2-driven mammary carcinomas halted cancer progression and triggered tumor-specific senescence, without compromising the animals' health. Ablation of cyclin D3 in mice bearing T-cell acute lymphoblastic leukemias (T-ALL) triggered tumorspecific apoptosis. Such selective killing of leukemic cells can be also achieved by inhibiting cyclin D associated kinase activity in mouse and human T-ALL models. Hence, contrary to what one might expect from ablation of a cell cycle protein, acute shutdown of a D-cyclin leads not only to cell cycle arrest, but it also triggers tumor cell senescence or apoptosis, and it affects different tumor types through distinct cellular mechanisms. Inhibiting cyclin D-activity represents a highly-selective anticancer strategy which specifically targets cancer cells without significantly affecting normal tissues. Mouse breast cancer V720 cells were cultured in the presence of the CDK4/6 inhibitor PD 0332991 (PD; 1 microM) or vehicle (VO) for 24 hrs. Experiment was done in biological triplicate. A total of 6 RNA samples (3 vehicle treated and 3 PD 0332991 treated samples) were used for microarray expression analysis.

2012-10-16 | E-GEOD-40513 | biostudies-arrayexpress

Exercise inhibits tumor progression and improves the therapeutic efficacy of PD-1 blockade in colorectal cancer preclinical models

Project description:Exercise training (ExT) has shown antitumor effects in many preclinical cancer models. In the present study, we utilize MC38 and CT26 cells, which represent MSI and MSS colorectal carcinomas respectively, to study the effects and mechanisms of ExT alone or in combination with PD-1 based immunotherapy. Using treadmill running and PD-1/PD-L1 blockade, we demonstrated that post-implant exercise training has broad anticancer activities in murine models of CRC. Specifically, in MSI CRC models, ExT induces beneficial metabolic and immunological adaptations, leading to a more significant inhibition in tumors treated with PD-1/PD-L1 blockade, suggesting a genotype-directed combinatory therapy for the subgroup of CRC patients. Moreover, ExT might be a safe and alternative anticancer strategy for cancers resistant to the PD-1 based immunotherapy, such as patients with MSS CRC tumors.

2021-04-16 | GSE172162 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data